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Co-morbid disease in COPD – more than a coincidence
Chronic obstructive pulmonary disease (COPD) is a major cause of disability and 
death worldwide. Its prevalence and mortality are increasing disproportionately among 
the elderly, women, persons of lower socioeconomic status, and the populations of 
developing countries (Anthonisen 1988; Borson et al 1998; Andreassen and Vestbo 
2003). There is increasing recognition that COPD is a complex disorder, with many 
associated co-morbidities. The term “co-morbid” has traditionally been interpreted as 
“a medical condition existing simultaneously but independently with another condition 
in a patient.” However, this does not seem to ﬁ  t the more recent research on patients 
with COPD as co-morbid conditions occur more frequently in these patients that 
would be expected by chance. Such conditions include cardiovascular disease (CVD) 
(Calverley and Scott 2006), depression (Borson et al 1998), diabetes (Schmidt et al 
1999), lung cancer (Omori et al 2006), and osteoporosis (Vogelmeier and Bals 2007). 
Some of these conditions may be worsened by COPD or complicated by COPD. For 
instance raised airway glucose concentrations in the airways that may occur in diabetes 
have been shown to precede an increase of respiratory pathogens (Baker et al 2006) 
and cardiovascular disease (CVD) is a very common cause of death in patients with 
COPD (Calverley and Scott 2006).
The paper by Anecchino and colleagues (2007) in this issue adds to the literature 
on the prevalence of co-morbidities in patients with COPD reporting on a study of the 
prevalence of COPD and 3 treated co-morbidities: CVD, depression and osteoporosis 
in Italy. This is an important study as it utilizes data from a large cohort of approxi-
mately 123,000 possible COPD patients. Of note is the high proportion (98%) of these 
patients who had been prescribed at least one “nonrespiratory” drug. 
We need however to be cautious in interpreting this data for a number of reasons. 
Patients in this study were deﬁ  ned as having COPD and the co-morbid conditions by 
drug treatment rather than having a speciﬁ  c diagnosis. This means the patients studied 
may have had other respiratory diseases such as asthma and that patients with untreated 
CVD, depression and osteoporosis are excluded. Unfortunately, the authors chose to 
report on just three speciﬁ  c co-morbidities, cardiovascular, diabetes and depression. 
It is hoped that the authors will go on to include other important co-morbidities such 
as osteoporosis.
There appear to be a number of mechanisms by which co-morbid conditions arise 
in patients with COPD other than by chance. The ﬁ  rst of these is sharing of common 
risk factors. These include poor socioeconomic status, smoking and age which are 
clearly risk factor for a large range of conditions. Indeed half of all people aged 65 years 
or older have been reported to have at least three chronic medical conditions, and a 
ﬁ  fth have ﬁ  ve or more (Boyd et al 2005). Another mechanism is the increasingly well 
described systemic effects of COPD (Fabbri and Rabe 2007). This systemic inﬂ  am-
mation is now thought to impact on extra-pulmonary organs such the heart and blood 
vessels as well as the metabolic system. In addition, the effects of COPD increases the 
risks of other conditions with breathlessness, inactivity, and exacerbations resulting 
in depression, anxiety, and inactivity with resulting osteoporosis risk and muscle loss. 
Finally, COPD treatment may in itself increase the risk of other conditions particularly 
those related to oral steroid usage. International Journal of COPD 2007:2(4)  400
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So what are the implications for management? Clearly, 
patients need a comprehensive assessment identifying and 
addressing co-morbidities. This should ideally be provided in 
a comprehensive way rather than a patient with COPD having 
fragmented care from a broad range of health professionals. 
This would include addressing common risk factors ie, age, 
smoking, and poor self-management of the primary chronic 
disease. Treatments need to be assessed that may address 
the systemic effects of COPD such the PDE-4 inhibitors and 
statins (Fabbri and Rabe 2007). Improving speciﬁ  c COPD 
outcome will improve some of its secondary effects such as 
depression and immobility. Finally, attempts should be made 
to minimise iatrogenic effects of COPD treatment particularly 
oral steroid therapy is clearly important.
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Obstructive sleep apnea (OSA) affects around 4% of middle-
aged men (Young et al 1993). With this high prevalence of 
OSA and the rising worldwide increase in morbidity and 
mortality in chronic obstructive pulmonary disease (COPD) 
(WHO 2000), it is not surprising that research attentions have 
focused on the overlap between these two highly prevalent 
conditions with the aim of determining their relationship. A 
number of studies have investigated the association between 
OSA and COPD. In patients with COPD, studies have shown 
that as the depth of sleep increases so there is a reduction in 
minute ventilation with an increase in upper airway resistance 
(Ballard et al 1995) with up to 20% patients with severe 
COPD exhibiting co-existent OSA (Brander et al 1992). 
Although the Sleep Heart Health Study (Sanders et al 2003) 
found that OSA prevalence was not increased in mild COPD, 
undiagnosed airways obstruction can be present in 10 
percent of patients with OSA (Lin and Huang 1992). These 
observations may simply reﬂ  ect that the clinical relevance of 
the overlap between COPD and OSA only become apparent 
when one or both of these conditions are severe. 
In this issue, Krieger and colleagues (2007) report on the 
respiratory disturbances that occur during sleep in COPD 
patients with mild airways obstruction. These researchers 
highlight that the differences in the literature pertaining to 
the incidence of nocturnal respiratory disturbance in COPD 
may be a consequence of inadequate techniques previously 
used to measure these events. Krieger and colleagues (2007) 
hypothesized that using more detailed measurements, such as 
measuring the arousal on the electroencephalogram in response 
to inspiratory ﬂ  ow limitation, or so called respiratory-effort 
related arousals (RERAs), in addition to standard respiratory 
measurements, COPD patients with daytime normoxia would 
have a greater severity of respiratory disturbance during sleep 
compared with non-COPD patients. However, in contrast to 
the original hypothesis, the authors showed that in a selected 
group of well-nourished (mean body mass index [BMI] 31 
kg/m2) COPD patients with mild airways obstruction (mean 
forced expiratory volume in one second [FEV1]/forced vital 
capacity [FVC] 63%), who were referred to a sleep centre to 
investigate snoring, the severity of respiratory disturbance and 
nocturnal hypoxemia were similar to patients without airways 
obstruction. In fact, the COPD patients overall had a tendency 
to have lower respiratory disturbances during sleep. 
Are these data novel and useful? Although not wholly 
novel, these data identify a number of useful clinical mes-
sages. In the group of patients studied, RERA measurements 
adds little to the standard respiratory measurements of ﬂ  ow 
and thoraco-abdominal movement, the apnea-hypopnea index 
(AHI), and so for the majority of cases it is acceptable to 
use AHI, which is technically less cumbersome to perform. International Journal of COPD 2007:2(4)  401
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In addition, COPD patients with mild airways obstruction 
referred to sleep centers for further investigation of snoring 
have a similar severity of sleep-disordered breathing as com-
pared with aged and BMI matched controls without COPD. 
These centres, therefore, can manage these COPD patients 
in a similar manner to other patients. Finally, the observation 
by Krieger and colleagues (2007) that the severity of airways 
obstruction, as evidence by FEV1/FVC ratio, was inversely 
related to BMI, but AHI directly related to the severity of 
airways obstruction is an interesting result. Furthermore, 
these investigators showed that BMI is less predictive of the 
variance in AHI in COPD than those without COPD. These 
ﬁ  ndings need some further discussion as body composition 
demographics in patients with COPD and OSA can be dis-
tinctly different. Indeed, it is established that there is a direct 
relationship between BMI and severity of OSA in patients 
without COPD such that a change in BMI is associated with 
change in AHI (Noseda et al 2006). In contrast, although body 
composition correlates with severe disease in COPD, there 
is an indirect relationship between body composition and 
disease severity such that a low BMI predicts poor outcome 
in COPD (Schols et al 2005). This adds to the complexity 
of the clinical problem and the results of the current study 
suggest that the correlations between severity of airways 
obstruction, BMI and severity of OSA do not necessarily 
extend to patients with COPD. In patients with COPD, one 
could predict that as airways obstruction increases so BMI 
would fall and thus AHI would decrease. However, this has 
still to be proven as the current study only investigated COPD 
patient with mild airways obstruction and preserved BMI. 
Despite AHI having 65% dependence on BMI, AHI had 
85% dependence on airways obstruction, suggesting there 
could be greater relative importance of airways obstruction 
than body composition in COPD patients. More research 
comparing nocturnal respiratory disturbances in mild COPD 
and severe COPD is required, with attention directed on the 
effect of body composition, severity of OSA and severity of 
airways obstruction.
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